Company profile
CoRegen, Inc.
Privately held: no public share price (Houston-based clinical-stage cell-therapy biopharmaceutical company (Treg cell therapy CRG-150), VC-backed with $121M+ raised total including a $93.4M round in July 2025. No roster match; Crunchbase/PitchBook list it as private and no ticker or exchange listing was found anywhere. Sources: https://clinicaltrials.gov/study/NCT07730125 ; https://api.gleif.org/api/v1/lei-records/2549000CDYS5YH6XDR52 ; https://api.gleif.org/api/v1/lei-records/984500EC7LEQEU100570 ; https://www.biospace.com/press-releases/coregen-inc-closes-more-than-93-million-financing ; https://tracxn.com/d/companies/coregen/__ggHJ4B-0a_hAPcFoNWeqO3BJ8yAZClD6npoGjIWZP9o Entity resolved by asset-pipeline-v2.)
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | Regulatory T-cell therapyCell therapy | HR+/HER2- Breast Cancer HR+/HER2- Metastatic Breast Cancer |
Upcoming events
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.